The Prognostic Impact of <i>FLT3</i> in <i>NPM1</i>-Mutated AML: Co-Occurrence of <i>FLT3-ITD</i> and <i>FLT3-TKD</i> Confers Poor Outcomes
Onyee Chan(Moffitt Cancer Center), David A. Sallman(Moffitt Cancer Center), Gail J. Roboz(Cornell University), Somedeb Ball(Vanderbilt University), Jeffrey E. Lancet(Cornell University), Eric Padron(Moffitt Cancer Center), Mohammad Hussaini(Moffitt Cancer Center), Andrew Kuykendall(Moffitt Cancer Center), Kendra Sweet(Moffitt Cancer Center), Hammad Tashkandi, Caroline Hana(Moffitt Cancer Center), Najla Al Ali(Moffitt Cancer Center), Yehuda E. Deutsch(Moffitt Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Justin Grenet(Cornell University), Rami S. Komrokji(Moffitt Cancer Center), Ling Zhang(Moffitt Cancer Center), Seongseok Yun(Moffitt Cancer Center)
Cited by 2
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k